Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulcerative Colitis
Clinical trial register · United States · industry-sponsored

Ulcerative Colitis Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 40 Florida 36 Georgia 25 Illinois 24 Arizona 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Takeda8 AbbVie5 Eli Lilly and Company5 Pfizer3 Sanofi3
State
California40 Florida36 Georgia25 Illinois24 Arizona22
All 36 states
Target enrolment
to

Ulcerative Colitis trials in the USA

46 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
NCT07250815Ulcerative Colitis, Crohn's Disease
Takeda
Observational
23,900
Massachusetts
2026-09-21
Recruiting
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Florida, Louisiana, Rhode Island, Texas, Washington
2026-06-08
Recruiting
Athos Therapeutics Inc
Phase 2
120
Florida, Georgia, Ohio
2026-04-30
Recruiting
Bristol-Myers Squibb
Observational
1,182
North Carolina
2026-04-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Recruiting
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Active, closed
Sanofi
Phase 2
105
California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri, New York
2025-07-07
Recruiting
Eli Lilly and Company
Phase 3
350
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Active, closed
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Recruiting
Takeda
Phase 2
192
Maryland, Texas
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Colorado, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland
2025-05-27
Recruiting
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Active, closed
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
Bristol-Myers Squibb
Observational
2,828
Minnesota
2024-08-26
Recruiting
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Active, closed
Takeda
Phase 2
213
California, Florida, Georgia, Kentucky, Maryland, Nevada, Rhode Island, South Carolina
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana
2024-03-27
Active, closed
AbbVie
Phase 2
156
California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2024-03-23
Active, closed
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Active, closed
AnaptysBio, Inc.
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Nevada, New York, Ohio
2023-12-04
Active, closed
AltruBio Inc.
Phase 2
50
California, Colorado, Florida, Indiana, Kentucky, Louisiana, Mississippi, New York
2023-12-04
Active, closed
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Recruiting
Bausch Health Americas, Inc.
Phase 4
70
California, Indiana, New York, North Carolina
2023-09-29
Recruiting
Takeda
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland
2023-05-16
Recruiting
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
NCT05666960Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Rise Therapeutics LLC
Phase 1
36
California, Florida, Minnesota
2023-02-27
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-01-16
Recruiting
Pfizer
Phase 2
36
Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2022-12-16
Active, closed
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
NCT05466890Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
Palatin Technologies, Inc
Phase 2
16
Arizona, California, Florida, Kansas, Louisiana, New Jersey, New York, Pennsylvania
2022-09-15
Active, closed
Pfizer
Phase 3
118
California, Connecticut, Florida, Georgia, Massachusetts, New York, Ohio, Pennsylvania
2021-08-12
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Massachusetts, Missouri, New York, Pennsylvania, Texas
2021-05-26
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2019-09-26
Active, closed
Pfizer
Phase 3
896
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2019-09-05
Active, closed
Eli Lilly and Company
Phase 3
1,058
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2018-07-18
Active, closed
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Target PharmaSolutions, Inc.
Observational
15,000
California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Louisiana
2017-07-24
Active, closed
Janssen Biotech, Inc.
Observational
535
California, Florida, Georgia, Illinois, Ohio, Pennsylvania, Texas, Virginia
2016-12-16
Active, closed
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
NCT00606346Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Janssen Biotech, Inc.
Observational
4,970
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2007-05-31
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/ulcerative-colitis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies listing the condition Ulcerative Colitis.

How many Ulcerative Colitis trials are recruiting in the US?

23 of the 46 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 21 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulcerative Colitis), 46 studies
PhaseStudiesRecruitingShare
Phase 219941.3%
Phase 315832.6%
Observational6113%
Phase 4336.5%
Not applicable112.2%
Phase 1112.2%
Phase 2/3102.2%

Most active sponsors

Lead sponsors with the most studies (Ulcerative Colitis)
Lead sponsorStudiesRecruiting
Takeda86
AbbVie52
Eli Lilly and Company53
Pfizer31
Sanofi32
Bristol-Myers Squibb21
Gilead Sciences20
Janssen Biotech, Inc.20
Merck Sharp & Dohme LLC21
Spyre Therapeutics, Inc.21

Top states

Top states (Ulcerative Colitis), by number of studies with a site there
StateStudies
California40
Florida36
Georgia25
Illinois24
Arizona22
Colorado20
New York13
Louisiana12
Alabama11
Indiana10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.